LONZA GROUP: Expects 11-12% CER Sales Growth for Full-Year 2026

NewTimeSpace News: On May 8, 2026, Lonza Group released its Q1 2026 business update. The company stated that despite challenges such as geopolitical and trade policy changes, its CDMO business remained strong and in line with expectations. Integrated Biologics, Advanced Synthesis and Specialized Modalities all delivered solid growth. In March 2026, the company signed an agreement to divest its Capsules & Health Ingredients business, marking the completion of its transformation into a pure-play CDMO.

According to the announcement, Lonza Group confirmed its full-year outlook, expecting 11-12% CER sales growth and CORE EBITDA margin expansion to above 32%.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.